At Novo Nordisk, we strive to be the world's leading diabetes care company, and each of us takes this vision personally. Our highest priority is the health and well being of people living with diabetes. We respect their many lifestyles and individual needs, and we develop our therapies with those differences in mind. Through intensive research, Novo Nordisk has created innovative insulin delivery systems as well as disposable needles that were designed to help reduce pain and fear of injection. Using recombinant technology, we have developed novel insulin and insulin analog formulations. We also offer patient education programs, support continuing medical education for healthcare professionals, and more, as we work to meet the individual needs of our customers.
In addition, we hold a leading position in other therapeutic areas, such as hemophilia, growth disorders, and hormone therapy for women.
Novo Nordisk employs approximately 26,000 full-time employees in 79 countries, and we reach 180 countries around the world with our products and programs. We operate manufacturing facilities in six nations, including the United States.
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy, and hormone therapy.
Stock info (NYSE quotes delayed by 15 minutes. Currency in USD)